DOCSLIB.ORG

Vital and Health Statistics; Series I3, No. 85 (6/86)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vital and Health Statistics; Series I3, No. 85 (6/86) Use of c tlmicrobial % in Offke= Based Practke unitedStates, 1-1 Data on the use of antimicrobial drugs during Offb visitstodk—bSSd physicians are presented. Emphask is placed on the types of drug used: peniallins, cephatosporins, macroliis and Iincosamides, tetraoyctks, the sulfonamides andkw trimethoptim, and miscellaneous antimicrobial medications. The level of use of the various types of drug is assessed by comparing drug mention frequencies and rates. The characteristics of the drugs used afso are investigated. Various aspects of the visits involving the use of these drugs are examined. These include the demogrephii characteristics of the patients who made the visits, patient complaints, dwnoees recoded, d~nostic and therapeutic sentices ordered or provided, patient disposMon, and visit duration. Dsts Ffomthe Nstiond H8elth Sunfey series Iq No. 8s DHHS Publiition No. (PHS) 86-1746 U.S. Department of Health and Human services PubIii Heanh service National Center for Health Statistics Hyattsville, Md. June 19S6 I Copyright Information The National Center for Health Stabs.tics has obtained permission from the copyright holders to reproduce ceriam quoted material in this report. Further reproduction of this material is prohibited without specific permission of the copyright holders. All other material contained in the reporl is in the public domain and may be used and reprinted without special permission; citation as to source, however, is appreciated. Suggested Citatiin National Center for Health Statistics, G. J. Gardocld: Use of antimicrobial drugs in office-based practice, United States, 1980-61. Vita/ and Hea/th Statistics. Series 13, No. 85. DHHS Pub. No. (PHS) 86-1746. Public Health Service Washington. U.S. Government Printing Gffice, June 1988. L~ry 01 Congress Cataloging-in~ Data Gardocld, Gloria J. Use of antimicrobial drugs in office-baaed practice. (Vital & health statistics. Series 13, Data from the national health survey; no. 85) (DHHS publication; (PHS) 66-1746) Author: Gloria J. Gardocki. Bibliography: p. $upt. of D~s. no.: HE20.6209:13/85 1. Drug utlltzatior+Unitad Statee-Statistics. 2. Anti-infective agente- Thera@utic usa-+tetktics. 3. Physician services utiliiatiin-Unitad States- Statistics. 1. National Center for Health Statiafks (U. S.) Il. Ttle. Ill. Vial and health statistics. series 13, Data from the national health suwey; no. 65. IV. Series: DHHS puMkation; no. (PHS) 6$-1746. [DNLM: 1. Anti-lnfaotive Agents+harapautic uflnitad Statea--atatistics. 2. Diug Utilization-United States-statistics. 3. Gffii Visits-United Statea-+teMca. W2 A NI 46vm no. 65] RM261 .3.U6G37 1966 61 S.329 66-60Wt29 ISBN 0-6406+331-2 lTor sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402 National Center for Health Statistics Manning Feinleib, M. D., Dr. P. H., Director Robert A. Israel, Deputy Director Jacob J. Feldman, Ph. D., Associute Director for Anulysis und Epidemiology Garrie J. Losee, Associute Director for Dutu Processing and Services Alvan O. Zarate, Ph. D., Assistant Director for international Statistics Peter L. Hurley, Acting Associute Director for Interview und Examination Statistics Stephen E. Nieberding, Associute Director for Management Gail F. Fisher, Ph. D., Associate Direclor for Program Planning, Evaluation, and Coordination Monroe G. Sirken, Ph. D., Associate Director for Research and Methodology Peter L. Hurley, Associate Director for Vital and Health Cure Statistics Alice Haywood, Information 0J7icer Vital and Health Care Statistics Program Peter L. Hurley, Associate Director Gloria Kapantais, Assistant to the Director for DUIUPolicy, Planning, and Analysis Division of Health Care Statistics W. Edward Bacon, Ph. D., Director Joan F. Van Nostrand, Deputy Director James E. Deiozier, Chief, Ambulatory Care Statistics Branch Introduction . ..l Information highlights . ........2 Data background . -. ...-..4 Scope of the report . 4 Data source and limitations.. -...--..4 Selection and classification of antimicrobial drugs . 5 Findings . - - ...--..10 Dmgmention information . - . - . - - . 10 Visit information . - . ...15 References . -....-.30 List of detailed tables . .. ...--.31 Appendmes , I. Technical notes . ...42 11. Definitions of certain terms used in this report . 49 111.Patient Log and Patient Record form . ...52 IV. American Hospital Formulary Service classification system and therapeutic categov codes . 53 Iistoftextfigures 1. Classification of antimicrobial generic entities appearing in the National Ambulatory Medical Care Survey: United States, 1980-81 ..-.-.. .. 6 2. Drugs named by physician respondents in reporting the order or provision of ’wnicillins: United States, 1980-81 . .................. ....” 7 3. Drugs named by physician respondents in reporting the order or provision of cephalosporins: United States, 1980-81 . .......”.....”..... .. 7 4. Drugs named by physician respondents in reporting the order or provision of macrolides and Iincosamides: United States, 1980-81 . .....-.......”...-. .. 7 5. Drugs named by physician respondents in reporting the order or provision of tetracycline: United States, 1980-81 . ..-. ................... .’ 8 6. Dregs named by physician respondents in reporting the order or provision of sulfonamides and trimethoprim: United States, 198(k81 . -. 8 7. Drugs named by physician respondents in reporting the order or provision of miscellaneous antimicrobial: United States, 1980-81 . .- 9 List of text tsbles A. Number and percent distribution of antimicrobial drug mentions, by type of antimicrobial drug: United States, 198&81 . ................... .- 10 B. Number and percent distribution of the 20 generic ingredients most frequently appearing in antimicrobial drug mentions: United States, 1980-81 . 11 C. Number and percent distribution of the 30 antimicrobial drugs most frequently mentioned in office-based practice: United States, 1980-81 . .....12 .. w D. Number and percent distribution of antimicrobial drug mentions, by American Hospital Formulary Service therapeutic category : United States, 1980-81 . 12 E. Number and percent distribution of antimicrobial drug mentions by composition status, according to type of antimicrobial drug: United States, 1980-81 . 13 F. Number and percent distribution of antimicrobial drug mentions by entry status, according to type of a,nti- microbial drug: United States, 1980-81 . 13 G. Number, percent distribution, and average annual rate (per 1,000 civilian noninstitutionalized population) of antimicrobial drug mentions by sex and age of patient, according to type of antimicrobial drug: United States, 198&81 . 14 H. Number and percent distribution of antimicrobial drug visits, by type of antimicrobial drug ordered or provided: United States, 1980--8l. 15 J. Number and percent distribution of antimicrobial drug visits by major reason for visit, according to type of antimicrobial drug ordered or provided: United States, 1980-81 . 16 K. Number and percent distribution of the 20 specific principal reasons for visit most commonly given during antimicrobial drug visits: United States, 198&81 . 16 L. Number and percent distribution of antimicrobial drug visits, by class of principal diagnosis: United States, 198W81 . 17 M. Number and percent distribution of the 20 specific principal diagnoses most commonly made during anti- microbial drug visits: United States, 1980-81 . 17 N. For visits associated with each type of antimicrobial drug, number and percent distribution of the most common specific principal diagnoses: United States, 1980-81 . 18 0. Number of all visits, number of antimicrobial drug visits, antimicrobial drug visits as a percent of all visits, and the most frequently mentioned types of antimicrobial drug, for each of the 20 principal diagnoses most commonly made during antimicrobial drug visits: United States, 1980-81 . 20 P. Number of all new-problem and return visits and percent of new-problem and return visits involving antimicrobial, for each of the 20 principal diagnoses most commonly made during antimicrobial drug visits: United States, 198@81 . 21 Q. Number, percent distribution, and average annual rate (per 1,000 civilian noninstitutionalized population) of antimicrobial drug visits by sex and age of patient, according to type of antimicrobial drug ordered or provicled: United States, 1980-81 . 22 R. Median age of patients making antimicrobial drug visits, by type and selected subtype of antimicrobial drug ordered orprovided: United States, 1980-81 . 23 S. Number and percent distribution of antimicrobial drug visits by physician specialty, according to type of antimicrobial drug ordered or provided: United States, 1980-81 . 24 T. Number and percent of antimicrobial drug visits, by type of antimicrobial drug ordered or provided and diagnostic service ordered or provided: United States, 1980-81 . 25 U. Number and percent of antimicrobial dmg visits, by type of antimicrobial drug ordered or provided and nonmedication therapeutic service ordered or provided: United States, 1980-81 . 26 W. Average number of co-occurring medications per antimicrobial drug visit, by type of antimicrobial drug ordered or provided and sex and age of patient United States, 1980-81 . 27 Y. Number and percent distribution of co-occurring drugs ordered or provided during antimicrobial dmg visits by therapeutic category of co-occurring dreg, according to type of antimicrobial drug ordered or provicled United States, 198&81 . 28 Z. Number and percent distribution of the 10 co-occurring drugs most
Load more

Recommended publications
  • Ceftazidime for Injection) PHARMACY BULK PACKAGE – NOT for DIRECT INFUSION
    PRESCRIBING INFORMATION FORTAZ® (ceftazidime for injection) PHARMACY BULK PACKAGE – NOT FOR DIRECT INFUSION To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibacterial drug for parenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4­ thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1­ azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6α,7β(Z)]]. It has the following structure: The molecular formula is C22H32N6O12S2, representing a molecular weight of 636.6. FORTAZ is a sterile, dry-powdered mixture of ceftazidime pentahydrate and sodium carbonate. The sodium carbonate at a concentration of 118 mg/g of ceftazidime activity has been admixed to facilitate dissolution. The total sodium content of the mixture is approximately 54 mg (2.3 mEq)/g of ceftazidime activity. The Pharmacy Bulk Package vial contains 709 mg of sodium carbonate. The sodium content is approximately 54 mg (2.3mEq) per gram of ceftazidime. FORTAZ in sterile crystalline form is supplied in Pharmacy Bulk Packages equivalent to 6g of anhydrous ceftazidime. The Pharmacy Bulk Package bottle is a container of sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous use. THE PHARMACY BULK PACKAGE IS NOT FOR DIRECT INFUSION, FURTHER DILUTION IS REQUIRED BEFORE USE.
    [Show full text]
  • Antibiotic Assay Medium No. 3 (Assay Broth) Is Used for Microbiological Assay of Antibiotics. M042
    HiMedia Laboratories Technical Data Antibiotic Assay Medium No. 3 (Assay Broth) is used for M042 microbiological assay of antibiotics. Antibiotic Assay Medium No. 3 (Assay Broth) is used for microbiological assay of antibiotics. Composition** Ingredients Gms / Litre Peptic digest of animal tissue (Peptone) 5.000 Beef extract 1.500 Yeast extract 1.500 Dextrose 1.000 Sodium chloride 3.500 Dipotassium phosphate 3.680 Potassium dihydrogen phosphate 1.320 Final pH ( at 25°C) 7.0±0.2 **Formula adjusted, standardized to suit performance parameters Directions Suspend 17.5 grams in 1000 ml distilled water. Heat if necessary to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Advice:Recommended for the Microbiological assay of Amikacin, Bacitracin, Capreomycin, Chlortetracycline,Chloramphenicol,Cycloserine,Demeclocycline,Dihydrostreptomycin, Doxycycline, Gentamicin, Gramicidin, Kanamycin, Methacycline, Neomycin, Novobiocin, Oxytetracycline, Rolitetracycline, Streptomycin, Tetracycline, Tobramycin, Trolendomycin and Tylosin according to official methods . Principle And Interpretation Antibiotic Assay Medium is used in the performance of antibiotic assays. Grove and Randall have elucidated those antibiotic assays and media in their comprehensive treatise on antibiotic assays (1). Antibiotic Assay Medium No. 3 (Assay Broth) is used in the microbiological assay of different antibiotics in pharmaceutical and food products by the turbidimetric method. Ripperre et al reported that turbidimetric methods for determining the potency of antibiotics are inherently more accurate and more precise than agar diffusion procedures (2). Turbidimetric antibiotic assay is based on the change or inhibition of growth of a test microorganims in a liquid medium containing a uniform concentration of an antibiotic. After incubation of the test organism in the working dilutions of the antibiotics, the amount of growth is determined by measuring the light transmittance using spectrophotometer.
    [Show full text]
  • 209627Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 209627Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review Reviewers of Multi-Disciplinary Review and Evaluation SECTIONS OFFICE/ AUTHORED/ ACKNOWLEDGED/ DISCIPLINE REVIEWER DIVISION APPROVED Mark Seggel, Ph.D. OPQ/ONDP/DNDP2 Authored: Section 4.2 Digitally signed by Mark R. Seggel -S CMC Lead DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=Mark R. Signature: Mark R. Seggel -S Seggel -S, 0.9.2342.19200300.100.1.1=1300071539 Date: 2018.08.08 16:29:15 -04'00' Frederic Moulin, DVM, PhD OND/ODE3/DBRUP Authored: Section 5 Pharmacology/ Digitally signed by Frederic Moulin -S Toxicology DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Reviewer Signature: Frederic Moulin -S 0.9.2342.19200300.100.1.1=2001708658, cn=Frederic Moulin -S Date: 2018.08.08 15:26:57 -04'00' Kimberly Hatfield, PhD OND/ODE3/DBRUP Approved: Section 5 Pharmacology/ Toxicology Digitally signed by Kimberly P. Hatfield -S DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Team Leader Signature: Kimberly P. Hatfield -S 0.9.2342.19200300.100.1.1=1300387215, cn=Kimberly P. Hatfield -S Date: 2018.08.08 14:56:10 -04'00' Li Li, Ph.D. OCP/DCP3 Authored: Sections 6 and 17.3 Clinical Pharmacology Dig ta ly signed by Li Li S DN c=US o=U S Government ou=HHS ou=FDA ou=People Reviewer cn=Li Li S Signature: Li Li -S 0 9 2342 19200300 100 1 1=20005 08577 Date 2018 08 08 15 39 23 04'00' Doanh Tran, Ph.D.
    [Show full text]
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
    [Show full text]
  • Antibacterial Residue Excretion Via Urine As an Indicator for Therapeutical Treatment Choice and Farm Waste Treatment
    antibiotics Article Antibacterial Residue Excretion via Urine as an Indicator for Therapeutical Treatment Choice and Farm Waste Treatment María Jesús Serrano 1, Diego García-Gonzalo 1 , Eunate Abilleira 2, Janire Elorduy 2, Olga Mitjana 1 , María Victoria Falceto 1, Alicia Laborda 1, Cristina Bonastre 1 , Luis Mata 3 , Santiago Condón 1 and Rafael Pagán 1,* 1 Instituto Agroalimentario de Aragón-IA2, Universidad de Zaragoza-CITA, 50013 Zaragoza, Spain; [email protected] (M.J.S.); [email protected] (D.G.-G.); [email protected] (O.M.); [email protected] (M.V.F.); [email protected] (A.L.); [email protected] (C.B.); [email protected] (S.C.) 2 Public Health Laboratory, Office of Public Health and Addictions, Ministry of Health of the Basque Government, 48160 Derio, Spain; [email protected] (E.A.); [email protected] (J.E.) 3 Department of R&D, ZEULAB S.L., 50197 Zaragoza, Spain; [email protected] * Correspondence: [email protected]; Tel.: +34-9-7676-2675 Abstract: Many of the infectious diseases that affect livestock have bacteria as etiological agents. Thus, therapy is based on antimicrobials that leave the animal’s tissues mainly via urine, reaching the environment through slurry and waste water. Once there, antimicrobial residues may lead to antibacterial resistance as well as toxicity for plants, animals, or humans. Hence, the objective was to describe the rate of antimicrobial excretion in urine in order to select the most appropriate molecule while reducing harmful effects. Thus, 62 pigs were treated with sulfamethoxypyridazine, Citation: Serrano, M.J.; oxytetracycline, and enrofloxacin. Urine was collected through the withdrawal period and analysed García-Gonzalo, D.; Abilleira, E.; via LC-MS/MS.
    [Show full text]
  • NPTC-Formulary Brief Acne
    Indian Health Service National Pharmacy and Therapeutics Committee Formulary Brief: Treatment of Acne vulgaris -January 2020- Background: The Indian Health Service (IHS) National Pharmacy and Therapeutics Committee (NPTC) reviewed the medical management of acne vulgaris at their January 2020 meeting. This review included topical therapies (retinoids, antibiotics, bactericidal and other anti-comedonal or anti-inflammatory agents) and oral therapies (antibiotics, isotretinoin, oral contraceptives, antiandrogens). Topical clindamycin, topical tretinoin, spironolactone, and combined estrogen-containing oral contraceptives are currently on the IHS National Core Formulary (NCF). Following clinical review, pharmacoeconomic evaluation and internal deliberation, the NPTC voted to ADD (1.) benzoyl peroxide (any topical formulation) and REPLACE topical clindamycin with (2.) combination clindamycin and benzoyl peroxide gel to the NCF. Discussion: Acne is the most common skin disorder in the United States (US), affecting 40-50 million persons of all ages. It can have significant sequelae from physical scarring, persistent hyperpigmentation, and psychological issues. Small studies focused on acne among American Indian/Alaska Native (AI/AN) populations suggest that the prevalence of acne is similar to other racial/ethnic groups in the US, but that the sequelae of scarring is significantly higher (55% in AI/AN vs. 3% among US white populations) and access to specialty care services is disproportionately low1. Acne is a chronic inflammatory disease of the pilosebaceous unit involving increased sebum production by sebaceous glands, hyperkeratinization of the follicle, colonization of the follicle by Propionobacterium acnes, and an inflammatory reaction. Acne is manifested with both non-inflammatory (open and closed comedones) and inflammatory lesions (papules, pustules, and nodules). Inflammatory acne is graded as mild, moderate, or severe based on the frequency of the various inflammatory lesions.
    [Show full text]
  • Impact of Retreatment with an Artemisinin-Based Combination On
    Muhindo Mavoko et al. Trials 2013, 14:307 http://www.trialsjournal.com/content/14/1/307 TRIALS STUDY PROTOCOL Open Access Impact of retreatment with an artemisinin-based combination on malaria incidence and its potential selection of resistant strains: study protocol for a randomized controlled clinical trial Hypolite Muhindo Mavoko1*, Carolyn Nabasumba2, Halidou Tinto3, Umberto D’Alessandro4,5, Martin Peter Grobusch6, Pascal Lutumba1 and Jean-Pierre Van Geertruyden7 Abstract Background: Artemisinin-based combination therapy is currently recommended by the World Health Organization as first-line treatment of uncomplicated malaria. Recommendations were adapted in 2010 regarding rescue treatment in case of treatment failure. Instead of quinine monotherapy, it should be combined with an antibiotic with antimalarial properties; alternatively, another artemisinin-based combination therapy may be used. However, for informing these policy changes, no clear evidence is yet available. The need to provide the policy makers with hard data on the appropriate rescue therapy is obvious. We hypothesize that the efficacy of the same artemisinin- based combination therapy used as rescue treatment is as efficacious as quinine + clindamycin or an alternative artemisinin-based combination therapy, without the risk of selecting drug resistant strains. Design: We embed a randomized, open label, three-arm clinical trial in a longitudinal cohort design following up children with uncomplicated malaria until they are malaria parasite free for 4 weeks. The study is conducted in both the Democratic Republic of Congo and Uganda and performed in three steps. In the first step, the pre-randomized controlled trial (RCT) phase, children aged 12 to 59 months with uncomplicated malaria are treated with the recommended first-line drug and constitute a cohort that is passively followed up for 42 days.
    [Show full text]
  • Clindamycin Plus Quinine for Treating Uncomplicated Falciparum Malaria: a Systematic Review and Meta-Analysis Charles O Obonyo1* and Elizabeth a Juma1,2
    Obonyo and Juma Malaria Journal 2012, 11:2 http://www.malariajournal.com/content/11/1/2 RESEARCH Open Access Clindamycin plus quinine for treating uncomplicated falciparum malaria: a systematic review and meta-analysis Charles O Obonyo1* and Elizabeth A Juma1,2 Abstract Background: Artemisinin-based combinations are recommended for treatment of uncomplicated falciparum malaria, but are costly and in limited supply. Clindamycin plus quinine is an alternative non-artemisinin-based combination recommended by World Health Organization. The efficacy and safety of clindamycin plus quinine is not known. This systematic review aims to assess the efficacy of clindamycin plus quinine versus other anti-malarial drugs in the treatment of uncomplicated falciparum malaria. Methods: All randomized controlled trials comparing clindamycin plus quinine with other anti-malarial drugs in treating uncomplicated malaria were included in this systematic review. Databases searched included: Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and LILACS. Two authors independently assessed study eligibility, extracted data and assessed methodological quality. The primary outcome measure was treatment failure by day 28. Dichotomous data was compared using risk ratio (RR), in a fixed effects model. Results: Seven trials with 929 participants were included. Clindamycin plus quinine significantly reduced the risk of day 28 treatment failure compared with quinine (RR 0.14 [95% CI 0.07 to 0.29]), quinine plus sulphadoxine- pyrimethamine (RR 0.17 [95% CI 0.06 to 0.44]), amodiaquine (RR 0.11 [95% CI 0.04 to 0.27]), or chloroquine (RR 0.11 [95% CI 0.04 to 0.29]), but had similar efficacy compared with quinine plus tetracycline (RR 0.33 [95% CI 0.01 to 8.04]), quinine plus doxycycline (RR 1.00 [95% CI 0.21 to 4.66]), artesunate plus clindamycin (RR 0.57 [95% CI 0.26 to 1.24]), or chloroquine plus clindamycin (RR 0.38 [95% CI 0.13 to 1.10]).
    [Show full text]
  • Demeclocycline
    PATIENT & CAREGIVER EDUCATION Demeclocycline This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. What is this drug used for? It is used to treat bacterial infections. It may be given to you for other reasons. Talk with the doctor. What do I need to tell my doctor BEFORE I take this drug? If you have an allergy to demeclocycline or any other part of this drug. If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you are taking penicillin. If you are breast-feeding or plan to breast-feed. This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs Demeclocycline 1/8 (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. What are some things I need to know or do while I take this drug? Tell all of your health care providers that you take this drug. This includes your doctors, nurses, pharmacists, and dentists. Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.
    [Show full text]
  • “The Red Face” and More Clinical Pearls
    “The Red Face” and More Clinical Pearls Courtney R. Schadt, MD, FAAD Assistant Professor Residency Program Director University of Louisville Associates in Dermatology I have no disclosures or conflicts of interest Part 1: The Red Face: Objectives • Distinguish and diagnose common eruptions of the face • Recognize those with potential implications for internal disease • Learn basic treatment options Which patient(s) has an increased risk of hypertension and hyperlipidemia? A B C Which patient(s) has an increased risk of hypertension and hyperlipidemia? A Seborrheic Dermatitis B C Psoriasis Seborrheic Dermatitis Goodheart HP. Goodheart's photoguide of common skin disorders, 2nd ed, Lippincott Williams & Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams & Wilkins. Seborrheic Dermatitis • Erythematous scaly eruption • Infants= “Cradle Cap” • Reappear in adolescence or later in life • Chronic, remissions and flares; worse with stress, cold weather • Occurs on areas of body with increased sebaceous glands • Unclear role of Malassezia; could be immune response; no evidence of overgrowth Seborrheic Dermatitis Severe Seb Derm: THINK: • HIV (can also be more diffuse on trunk) • Parkinson’s (seb derm improves with L-dopa therapy) • Other neurologic disorders • Neuroleptic agents • Unclear etiology 5MinuteClinicalConsult Clinical Exam • Erythema/fine scale • Scalp • Ears • Nasolabial folds • Beard/hair bearing areas Goodheart HP. Goodheart's photoguide of common skin disorders, 2nd ed, Lippincott • Ill-defined Williams & Wilkins, Philadelphia
    [Show full text]
  • TETRACYCLINES and CHLORAMPHENICOL Protein Synthesis
    ANTIMICROBIALS INHIBITING PROTEIN SYNTHESIS AMINOGLYCOSIDES MACROLIDES TETRACYCLINES AND CHLORAMPHENICOL Protein synthesis Aminoglycosides 1. Aminoglycosides are group of natural and semi -synthetic antibiotics. They have polybasic amino groups linked glycosidically to two or more aminosugar like: sterptidine, 2-deoxy streptamine, glucosamine 2. Aminoglycosides which are derived from: Streptomyces genus are named with the suffix –mycin. While those which are derived from Micromonospora are named with the suffix –micin. Classification of Aminoglycosides 1. Systemic aminogycosides Streptomycin (Streptomyces griseus) Gentamicin (Micromonospora purpurea) Kanamycin (S. kanamyceticus) Tobramycin (S. tenebrarius) Amikacin (Semisynthetic derivative of Kanamycin) Sisomicin (Micromonospora inyoensis) Netilmicin (Semisynthetic derivative of Sisomicin) 2. Topical aminoglycosides Neomycin (S. fradiae) Framycetin (S. lavendulae) Pharmacology of Streptomycin NH H2N NH HO OH Streptidine OH NH H2N O O NH CHO L-Streptose CH3 OH O HO O HO NHCH3 N-Methyl-L- Glucosamine OH Streptomycin Biological Source It is a oldest aminoglycoside antibiotic obtained from Streptomyces griseus. Antibacterial spectrum 1. It is mostly active against gram negative bacteria like H. ducreyi, Brucella, Yersinia pestis, Francisella tularensis, Nocardia,etc. 2. It is also used against M.tuberculosis 3. Few strains of E.coli, V. cholerae, H. influenzae , Enterococci etc. are sensitive at higher concentration. Mechanism of action Aminoglycosides bind to the 16S rRNA of the 30S subunit and inhibit protein synthesis. 1. Transport of aminoglycoside through cell wall and cytoplasmic membrane. a) Diffuse across cell wall of gram negative bacteria by porin channels. b) Transport across cell membrane by carrier mediated process liked with electron transport chain 2. Binding to ribosome resulting in inhibition of protein synthesis A.
    [Show full text]
  • Abnormal Vaginal Discharge: What Does and Does Not Work in Treating Underlying Causes
    AE_French.1104.final 10/18/04 11:03 AM Page 890 Applied Evidence N EW R ESEARCH F INDINGS T HAT A RE C HANGING C LINICAL P RACTICE Abnormal vaginal discharge: What does and does not work in treating underlying causes Linda French, MD Michigan State University, East Lansing, Mich Jennifer Horton, DO Genesys Regional Medical Center Family Practice Residency, Grand Blanc, Mich Michelle Matousek, DO Henry Ford Health System, Detroit, Mich Practice recommendations part of this article, “Abnormal vaginal discharge: Using office diagnostic testing more effectively” ■ Treat bacterial vaginosis with oral or intravagi- (JFP 2004; 53[10]:805–814), abnormal discharge nal metronidazole or with clindamycin (SOR: is more likely to be bacterial vaginosis or no A); recurrences are common (SOR: C). pathogen at all. Potential delay in diagnosis and treatment of a sexually transmitted disease is ■ Oral and intravaginal imidazoles are also a concern. Increasing resistance of Candida equally effective in the treatment of sp. to imidazoles is associated with indiscriminate candidiasis (SOR: A); alternate therapies use of over-the-counter products. for resistant cases have been little studied. ■ Oral metronidazole is the standard ■ BACTERIAL VAGINOSIS therapy for trichomoniasis (SOR: A). The standard treatment for bacterial vaginosis Oral tinidazole, newly available in the (BV) has been oral metronidazole (Flagyl) 500 mg US in 2004, should be used in resistant twice daily for 5 to 7 days. Intravaginal 0.75% cases (SOR: B). metronidazole gel (MetroGel) has been shown to be as effective as oral metronidazole (SOR: A).1,2 Oral metronidazole can cause nausea and ntifungal medications for intravaginal use abdominal pain in some patients; vaginal treat- have been available in the United States ment may be preferable for them.
    [Show full text]